ESMO 2017

Frozen Gloves Reduced Chemotherapy-Induced PN, Improved Quality of Life

Frozen Gloves Reduced Chemotherapy-Induced PN, Improved Quality of Life

By

Quality of life for patients with CIPN was improved by wearing frozen gloves during treatment. Researchers reported in an oral presentation at ESMO 2017 Congress that the gloves reduced symptoms even though long-term differences in neuropathy were not observed.

Sarcopenia Affects Dose in Reinduction Therapy for Metastatic Colorectal Cancer

Sarcopenia Affects Dose in Reinduction Therapy for Metastatic Colorectal Cancer

By

Sarcopenia is significantly associated with dose reductions but not with dose-limiting toxicities at initiation of CAPOX-B reinduction therapy in patients with mCRC, researchers reported at ESMO 2017 Congress.

Cannabis Reduces Response Rate to Immunotherapy for Cancer

Cannabis Reduces Response Rate to Immunotherapy for Cancer

By

Investigators report that administering cannabis to patients with cancer undergoing immunotherapy was found to lower the response rate to therapy but had no effect on PFS or OS, in an oral presentation at ESMO 2017 Congress.

Prevalence of Aggressive Cancer Care at End of Life Remains Unchanged

Prevalence of Aggressive Cancer Care at End of Life Remains Unchanged

By

Researchers reported trends of aggressiveness of cancer care near the end of life (ACCEoL) have remained unchanged in adult patients despite increasing resources for integrated palliative care in a presentation at ESMO 2017 Congress.

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications

By

Patients with multiple myeloma treated with daratumumab who experience IRRs may easily be managed by administering pre-infusion and postinfusion medications, investigators reported in a presentation at ESMO 2017 Congress.

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

Niraparib Maintains Quality of Life in Recurrent Ovarian Cancer

By

Administering niraparib to patients with recurrent ovarian cancer after CR or PR to platinum-based chemotherapy may allow patients to continuously maintain QOL during treatment, reported researchers in presentation at ESMO 2017 Congress.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs